Pharsight

Drugs that contain Tenofovir Alafenamide Fumarate

1. Vemlidy patents expiration

VEMLIDY's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7390791 GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Apr, 2025

(10 months from now)

US9296769 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

US8754065 GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7803788 GILEAD SCIENCES INC Prodrugs of phosphonate nucoleotide analogues
Feb, 2022

(2 years ago)

US7390791

(Pediatric)

GILEAD SCIENCES INC Prodrugs of phosphonate nucleotide analogues
Oct, 2025

(1 year, 4 months from now)

US8754065

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

US9296769

(Pediatric)

GILEAD SCIENCES INC Tenofovir alafenamide hemifumarate
Feb, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Oct 17, 2025
New Chemical Entity Exclusivity(NCE) Nov 05, 2020
M(M-255) Feb 04, 2023
M(M-266) Aug 22, 2023
New Product(NP) Nov 11, 2019

NCE-1 date: 06 November, 2019

Market Authorisation Date: 10 November, 2016

Treatment: Treatment of chronic hepatitis b in adult patients; Treatment of chronic hepatitis b in adults and pediatric patients 12 years of age and older

Dosage: TABLET;ORAL

How can I launch a generic of VEMLIDY before it's drug patent expiration?
More Information on Dosage

VEMLIDY family patents

Family Patents